short-right-arrow logoMobile media-pie 1 7 % share download email linkedin round-download

Privacy Preference Centre

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. We use two types of cookies on our website: cookies which are necessary for this website to function and analytics cookies. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies used

  • CookieNotice
  • CookieAnalytics


Analytics Cookies

These are Google Analytics cookies which allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site and social media platforms All information these cookies collect is aggregated and therefore anonymous. This cookie is defaulted to ‘Active’, which means we will be able to track, on any anonymous basis, how many visitors we have to our site, and monitor its performance. If you wish to turn them off you can do so by unticking ‘Active’ and clicking ‘Save and Accept Cookies’. For more information on how these cookies work, including a link through to the Google Privacy Policy which sets out further information about data which Google may collect in the course of providing us with Analytics.

Cookies used

  • _ga

Targeting Cookies

We use necessary cookies to make our site work. We also use analytics cookies which collect information about how visitors use our website and help us to improve it; these are defaulted to ‘Active’, if you wish to turn them off you can do so through the Cookie Settings. Please be aware that by blocking some types of cookies it may impact your experience of the site and the services we are able to offer. For more information about any of these cookies and our use of them, or to change your settings at any time, please see Cookie Settings and our Cookies Policy.

Bridgepoint in the News

06 August 2012

Bridgepoint sells Aenova

Funds advised by BC Partners (“BC Partners”) are acquiring the Aenova Group, one of the leading international service providers in the pharmaceuticals and health care industry. A contract to this effect was signed today with the previous majority shareholder Bridgepoint. The parties have agreed not to disclose the purchase price. The transaction is subject to antitrust clearance.

"As Europe's leading service provider in the development, manufacture and marketing of pharmaceuticals and dietary supplements for a broad range of customers in the pharmaceuticals and healthcare sector, Aenova is superbly positioned," says Stefan Zuschke, a managing partner at BC Partners. "In addition to continued organic growth, we are also planning further acquisitions to broaden the company's range and to additionally enhance its competitive position in the international markets." He adds that he is particularly pleased that the management team led by CEO Heiner Hoppmann and CFO/CPO Frank Elsen will remain at the company's helm.

"During Bridgepoint's ownership Aenova has been transformed by management into one of Europe's leading contract development and manufacturing organisations making it a key partner for many of Europe's leading blue chip pharmaceutical companies. Aenova is well invested and has strong prospects for further growth" said Michael Davy, a partner at Bridgepoint and Chairman of Aenova.

Says Aenova CEO Heiner Hoppmann: "BC Partners is management's preferred partner as we will be able to continue and expand our proven strategy of customer centricity, quality, innovation and growth."

Bridgepoint first invested in Aenova in 2005.

Advisers for Bridgepoint on this transaction included: PWC (financial and tax), BCG (commercial), Clifford Chance (legal), ERM (environmental), M+W (operational), Marsh (insurance).

Close

Contact us

If you are interested in working for Bridgepoint, please complete the form below.

Close

Investor reports registration

To access investor reports through the web based reporting facility, please fill in the form to register for an account.

The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.

Close

Request a copy of The Point

Mandatory fields are marked as (required*)